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Abstract
Bid is the only known Bcl-2 family member that can
function as an agonist of proapoptotic Bcl-2–related
proteins such as Bax and Bak. Expression of the
proapoptotic Bcl-2 family protein Bid was assessed by
immunoblotting and immunohistochemical methods in
normal murine and human tissues, and in several types
of human cancers and tumor cell lines. Bid expression in
normal tissues varied widely, with prominent Bid immu-
nostaining occurring in several types of short - lived cells
(e.g., germinal center B cells, peripheral blood granulo-
cytes, differentiated keratinocytes) and in apoptosis-
sensitive cells (e.g., adult neurons). Analysis of Bid
expression by immunostaining of 100 colon, 95 ovarian,
and 254 prostate cancers, as well as 59 brain tumors and
50 lymphomas, revealed evidence of altered Bid regu-
lation in some typesof cancers.Correlationswith clinical
outcomedata revealedassociationofhigher levels ofBid
with longer recurrence-free survival in men with locally
advanced (T3 stage) prostate cancer (P=0.04). Immuno-
blot analysis of Bid protein levels in the NCI’s panel of 60
human tumor cell lines revealed a correlation between
higher levels of Bid and sensitivity to ribonucleotide
reductase (RR) - inhibiting drugs (P<0.0005). Over-
expression of Bid in a model tumor cell line by gene
transfection resulted in increased sensitivity to apopto-
sis induction by a RR inhibitor. Taken together, these
observations suggest a potential role for Bid in tumor
responses to specific chemotherapeutic drugs, and lay a
foundation for future investigationsof thismemberof the
Bcl-2 family in healthy and diseased tissues.
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Introduction
Apoptosis is an evolutionary conserved process by which
multicellular organisms cleanly remove noninstructed, mis-
instructed, and damaged cells to ensure proper embryonic
development, maintenance of tissue homeostasis, and
immunologic defense [1]. The Bcl -2 family of proteins plays
a key role in processes underlying programmed cell death.
This gene family is comprised of antiapoptotic members such
as Bcl -2, Bcl -XL, Bcl -w, Mcl -1, Bfl -1, and Bcl -B and
proapoptotic proteins, which include Bax, Bak, Bad, Bok,
Bik, Bid, Bim, Hrk, Blk, Bnip3, Noxa, Puma, and Bcl -G. One
of the features of Bcl -2 family proteins is the formation of
homo- and heterodimers, whose relative abundance coin-
cides with either cell death or survival [2,3 ]. Four conserved
domains, called Bcl -2 Homology (BH) domains have been
identified in the members of this family [4,5 ]. The BH3
domain, in addition to being a protein–protein interaction
domain, is also required for the death-promoting function of
many proapoptotic molecules [6–8]. Several proapoptotic
members of the Bcl -2 family possess sequence homology
only to the BH3 amphipathic  helical domain. These
proteins, termed ‘‘BH3 only,’’ include Bid, Bik, Bad, Bim,
Blk, Hrk, Noxa, Puma, and Bcl -GS of mammals and EGL-1
of Caenorhabditis elegans [9–19].
Bid is a BH3-only protein that promotes cell death. Of all of
the 26 human Bcl -2 family members, Bid is the only one that
has been determined to function as an agonist of proapop-
totic Bcl -2 family proteins Bax and Bak [11]. Thus, Bid has
special status among the Bcl -2 family members. The Bid
protein shares structural similarity with multidomain Bcl -2
family proteins, which are known to be capable of integrating
into membranes and forming ion channels or pores [20,21].
Pore formation by Bid, however, requires removal of an N-
terminal autorepression domain [22].
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One in vivo mechanism for activating Bid involves
apoptosis- inducing members of the tumor necrosis factor
(TNF) family of cytokine receptors. Unlike many Bcl -2 family
proteins, Bid lacks a carboxyl - terminal membrane-anchor-
ing segment and resides mostly in the cytosol of healthy cells
[11]. However, the Bid protein can be activated by
proteolysis, resulting in its targeting to membranes. Inactive
cytosolic p22 Bid is activated through cleavage by caspase-
8 following triggering of Fas or TNF receptor 1 (TNFR1)
[23–25]. The caspase-8 mediated activation of Bid repre-
sents an amplification step in the presence of low caspase-8
levels, recruiting mitochondria into the cell death mechanism
[26]. Specifically, caspase-mediated cleavage results in a
rapid translocation of the p15 active COOH fragment of Bid
(containing the BH3 domain) to mitochondria. Truncated Bid
binds latent proapoptotic Bcl -2 family members Bax and
Bak, inducing their oligomerization in mitochondrial mem-
branes, and leading to formation of pores that release
cytochrome c [23–25,27–31]. The release of cytochrome c
from mitochondria promotes the oligomerization in the
cytosol of a cytochrome c /Apaf -1 /caspase-9 complex,
which activates caspase-9 and results in the cleavage of
downstream effector proteases, caspase-3, -6 and -7 [32].
An intact BH3 domain within tBid is required for cytochrome c
release, but not for targeting mitochondria [31]. Truncated
Bid has at least a 10- fold higher affinity toward Bcl -XL and is
100 times more efficient in inducing cytochrome c release
frommitochondria compared to its full - length precursor [23].
Thus, Bid connects the TNF family death receptor (extrinsic )
pathway for apoptosis and the mitochondria ( intrinsic)
pathway. Cardiolipin, present in the mitochondrial mem-
branes, has been reported to mediate targeting of tBid to
mitochondria by providing a membrane environment con-
ducive to Bid insertion [33]. The posttranslational N-
myristoylation of Bid also enhances insertion of this protein
into the outer mitochondrial membrane, release of cyto-
chrome c, and cell death [34].
Another mechanism for Bid activation involves granzyme
B, a serine aspartyl protease injected into target cells by
cytosolic T cells and natural killer (NK) cells [35,36].
Granzyme B directly cleaves Bid, generating a 14-kDa
truncated Bid fragment ( ‘‘gtBid’’ for granzyme B truncated),
and causing caspase- independent disruption of mitochon-
drial function and cytochrome c release [23,37–39].
A third mechanism for Bid activation involves a rather
indirect route. Several reports have demonstrated that
caspase-8, and its substrate Bid, are activated in response
to certain apoptotic stimuli in a death receptor– independ-
ent manner, representing a relatively late event in the
mitochondrial pathways for apoptosis [40,41]. Thus, in
some cell - and/or signal - type specific scenarios, cyto-
chrome c–mediated activation of caspase-9 and -3 can
lead to downstream activation of caspase-8 and subse-
quent cleavage of Bid [42].
Finally, in addition to caspase-dependent cleavage of
Bid, lysosomal proteases have also been shown recently to
generate similar length cleaved fragments of this protein,
which are competent to induce cytochrome c release from
mitochondria [43]. Thus, Bid proteolytic cleavage can be
executed in four distinct apoptotic pathways: 1) as an early
event in the extrinsic death receptor pathway, 2) as a late
event in the intrinsic mitochondrial pathway, 3) granzyme B,
and 4) lysosomal proteases [43–45].
The aim of the present study was to provide an overview
of the in vivo expression of Bid in normal tissues and
cancers, thus providing a better understanding of its




Polyclonal antisera for Bid were generated in rabbits using
synthetic peptides or recombinant protein immunogens. A
peptide (NH2–CSDNSFRRELDALGHELPVLAPQ–amide)
corresponding to residues 28 to 50 of huBid, was synthe-
sized with an N- terminal cysteine appended to permit
conjugation to maleimide-activated carrier proteins KLH
and OVA (Pierce, Rockford, IL), as described previously
[46,47]. This peptide conjugate was used to generate a
polyclonal antiserum (AR-54) in rabbits. Two additional
anti -Bid sera were generated in rabbits using recombinant
protein immunogens. Wild- type mouse BID (AR-52) and
BID1–55 (AR-53) were produced as GST fusion proteins
from pGEX vectors using Escherichia coli BL21 (DE3) as the
host strain. The protein purification method has been
described previously [22].
New Zealand white female rabbits were injected subcuta-
neously with a mixture of 0.25 ml KLH-peptide (1 mg/ml),
0.25 ml OVA-peptide (1 mg/ml), or recombinant protein
(0.1 to 0.25 g protein per immunization) and 0.5 ml
Freund’s complete adjuvant (dose divided over 10 injection
sites) and then boosted three times at weekly intervals,
followed by another 3 to 20 boostings at monthly intervals
with 0.25 mg each of KLH-peptide, OVA-peptide, or
recombinant protein immunogens in Freund’s incomplete
adjuvant, collecting blood at 1 to 3 weeks after each boosting
to obtain immune serum.
Tissue Preparation
Normal tissues for immunohistochemical analysis were
derived either from human biopsy and autopsy material
(n5; Department of Pathology, UCSD, San Diego) or from
adult mice of various strains. The tissues were fixed in either
neutral -buffered formalin, zinc-buffered formalin (Z- fix;
Anatech, Battle Creek, MI), B5, or Bouin’s solution (Sigma,
St. Louis, MO), and embedded in paraffin.
Archival Tumor Specimens
Ovarian cancer specimens derived from 95 patients
presenting to the Department of Gynecology and Obstetrics
of the University of Freiburg/Germany between 1993 and
1998 were included in this study. Clinical data including
survival and chemoresponse data were available until July
2000, representing a median follow-up of 35 months.
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The prostate cancer specimens were obtained from the
archives of the Institutes for Pathology, University of Basel
(Basel, Switzerland), the Cantonal Institute for Pathology
(Liestal, Switzerland) and the Tampere University Hospital
(Tampere, Finland). Tissue samples included 137 primary
tumors with stage T1 according to International Union
Against Cancer criteria [48], incidentally discovered after
transurethral resection for presumed BPH, and 117 primary
tumors treated by radical prostatectomy, including 38 speci-
mens with clinical stage T1 to T2 and 79 locally advanced
tumors (clinical stage T3).
The colon carcinoma specimens derived from100 patients
were received from the Department of Pathology, Yonsei
University, College of Medicine, Seoul, Korea. All specimens
presented stage II tumors (AJCC/UICC). The patients were
treated by surgical resection of the involved segment of colon.
No postoperative chemotherapy was performed.
Archival paraffin blocks from 59 glioma cases, including
15 astrocytomas, 11 glioblastomas, 20 oligodendrogliomas,
and 13 ependymomas were obtained from the Department of
Neuropathology at the University of Du¨sseldorf, Germany.
Non-Hodgkin’s lymphoma (NHL) specimens employed
for these studies represented archival paraffin blocks
obtained from ECOG trial (#6491). The material included
29 diffuse large lymphomas, 12 follicular lymphomas and
9 cases containing both components.
Tissue Array Construction
For the characterization of Bid expression in normal
tissues, we constructed two tissue microarrays each con-
taining 130 specimens, representing 0.6- or 1-mm (diam-
eter) cylindrical cores acquired from paraffin blocks of normal
human or mouse tissues which were sectioned at 4- to 5-m
thickness. To construct ovarian cancer, colon cancer, and
glioma tissue microarrays, two to five cylinders of 1-mm-
diameter tissuewere taken from representative areas of each
archival paraffin block and arrayed into a new recipient
paraffin block with a custom-built precision instrument
(Beecher Instruments, Silver Spring, MD). Serial sections (4
m) were applied to 3-aminopropyltriethoxysilane (APES)–
coated slides (Sigma), as described [49]. These materials
had been fixed in 8% formalin and paraffin-embedded
according to routine procedures. The prostate tissue micro-
array was constructed as described previously [50].
Immunohistochemistry
Dewaxed tissue sections were exposed to polyclonal
antibodies (PABs) generated against synthetic peptides and
confirmed to be specific for Bid. The sections were
immunostained using a diaminobenzidine (DAB)-based
detection method as described in detail, employing either
an avidin–biotin complex reagent (Vector Laboratories,
Burlingame, CA) [47] or the Envision-plus-horse radish
peroxidase (HRP) system (DAKO, Carpinteria, CA) using
an automated immunostainer (Dako universal staining
system) [51]. The dilutions of antisera typically employed
were 1:3000 (v /v) for AR-54, and 1:8000 for AR-52 and
AR-53.
For all tissues examined, the immunostaining procedure
was performed in parallel using preimmune serum to verify
specificity of the results. Initial confirmations of antibody
specificity also included experiments in which antiserum was
preabsorbed with 5 to 10 g/ml of either synthetic peptide
immunogen or recombinant protein immunogen.
The immunostaining results were arbitrarily scored
according to intensity as 0, negative; 1+, weak; 2+ ,
moderate; and 3+, strong. For lymphomas, samples were
additionally scored for percentage of immunopositive malig-
nant cells, estimating the percentage in increments of 10%
(0%, 10%, 20%, 30%, and so on) from a minimum of five
representative medium-power fields. Comparisons were
made with the germinal centers from non-neoplastic lymph
nodes (n=6). The scoring of immunostaining for all other
tumors was based on the percentage of immunopositive
cells (0 to 100) multiplied by staining intensity score (0/1/2 /
3), yielding scores of 0 to 300.
Statistical Analysis
Data were analyzed using the JMP Statistics software
package (SAS Institute, Cary, NC), and STATISTICA
Software (StatSoft, Tulsa, OK). Comparisons of Bid
immunostaining data with patient survival were made using
the Kaplan-Meier method. An unpaired t test method was
used for correlation of Bid immunoscores with the available
patient data. For the ovarian cancer analysis, statistical
significance of differences in clinical responses to chemo-
therapy was assessed using the unpaired t test and 2 test,
where nonresponders (NRs) were compared with patients
who achieved either partial response or complete response
(R for responders).
Cell Isolation and Culture
Established tumor cell lineswere cultured in eitherRPMI or
DMEM with 10% FBS [52]. These cell lines included the NCI
panel of 60 human tumor cell lines [53], plus 13 additional
human cancer cell linesmaintained in our laboratory: 7 breast
cancer cell lines (231, BT474, HS574, A1N4, 10A, 468 and
ZR751), 5 prostate cancer lines (PPC1, ALVA31, JCA1,
LNCap and TSU-PRL) and the lymphoma line RS11846.
A total of 4104 PC-3 cells were seeded in six-well plates
(30 mm diameter ) and transfected with 3 g of either
pcDNA3 or pcDNA3-Bid using lipofectamine-plus reagent
(Gibco-BRL, Grand Island, NY). After 24 h, cells were left
untreated or were treated with 10 nM pyrimidine 5-
glycodialdehyde, and incubated for another 24 hours before
assessing the induction of apoptosis by staining of cells with
5 g/ml of Hoechst reagent (Aldrich, Milwaukee, WI).
Immunoblotting
Mouse and human tissue lysates as well as lysates from
cultured cells were normalized for total protein content (50 g
and 100 g per lane, respectively) and subjected to SDS-
PAGE/ immunoblot analysis, using 1:1000 to 1:5000 (v/v)
dilutions of anti -Bid antisera, and secondary HRP con-
jugated goat anti–rabbit antibody (1:3000 v/v dilution)
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(Bio-rad, Hercules, CA), with detection accomplished using
an enhanced chemiluminescence (ECL) (Amersham-
based) multiple antigen detection (MAD) immunoblotting
method that allows for multiple reprobings of blots without
antibody stripping, as described previously [54,55].
Plasmids encoding Bcl -2, Bcl -XL, Bax, Bak, Bid, and Bad
were translated in TNT-reticulocyte lysates using either T3 or
T7 RNA polymerase (Promega) according to the manufac-
turer’s protocol, in the presence of [35S] - labeled L-methio-
nine (1 mCi /mmol) (Amersham, Piscataway, NJ).
Translation reactions (5 l ) were subjected to SDS-PAGE/
immunoblot analysis (Figure 1A ), using polyclonal Bid
antiserum (AR-54) andECL (Amersham) detectionmethod.
Statistical Analysis of Cell Line Data
Comparisons of Bid protein levels and in vitro chemo-
sensitivity data for the NCI panel of 60 human tumor cell lines
resulted in a rank–order correlation. P values were
calculated from two- tailed t distributions and Pearson
correlation coefficients and adjusted using a Bonferroni
correction for multiple correlations [53].
Results
Characterization of Anti -Bid Antibodies
The antisera were raised against huBid amino acids 28 to
50 (AR-54), and against recombinant proteins fusing GST to
either a full - length mouse Bid (AR-52) or a fragment of
mouse Bid containing amino acids 1 to 55 (AR-53). When
tested against several in vitro translated Bcl -2 family proteins
by immunoblotting, these antisera reacted only with Bid
(Figure 1A ). Figure 1B shows the analysis by SDS-PAGE
and fluorography of each translation reaction, confirming
synthesis of the [35S]- labeled Bcl -2 family proteins. These
anti -Bid antisera also displayed specific reactivity against
recombinant Bid protein produced in bacteria (Figure 1C ).
Immunoblot Analysis of Bid in Normal Tissues
Detergent lysates were prepared from normal mouse
tissues, normalized for total protein content, and analyzed by
SDS-PAGE/ immunoblotting using antisera specific for Bid.
Themost abundant amounts of the Bid protein were detected
in lymph node, spleen, spinal cord, cerebrum, cerebellum,
peripheral nerve, and heart. Bid was far less prevalent in
mouse thymus and skeletal muscle (Figure 1C ).
The endogenous 22-kDa mouse Bid protein was the
most abundant band detected in SDS-PAGE/ immunoblot
assays (Figure 1C ). However, additional minor bands of
lower molecular weight were seen in some cases, presum-
ably representing cleaved or partial degradationBid products,
which may arise during tissue harvesting or processing.
Someof these smaller forms of Bid do not appear to represent
caspase-cleaved Bid, based on comparisons of their
mobility in SDS-PAGE with recombinant tBid (15 kDa).
Immunohistochemical Analysis of Bid in Normal Mouse and
Human Tissues
Using antisera specific for Bid, the in vivo patterns of
expression of this protein were examined in normal human
Figure 1. Bid antibody specificity and expression of Bid protein in normal mouse tissues characterized by immunoblotting. The in vitro translated Bcl - 2, Bcl -XL, Bax,
Bak, Bid, and Bad proteins were subjected to SDS-PAGE / immunoblot analysis ( panel A ), using polyclonal Bid antiserum (AR-54 ). Incubation with Bid antiserum
detected only Bid in vitro translated protein. Panel B shows the analysis by SDS -PAGE and fluorography of each translation reaction, confirming synthesis of the
Bcl - 2 family proteins. In (C ), lysates from various mouse tissues were normalized for total protein content ( 50 g per lane ) and subjected to SDS -PAGE /
immunoblot analysis using mouse - specific AR -52. As a control, recombinant GST, caspase -9, XIAP, and Bid proteins were also included in the gel ( 10 ng ).
Arrowheads indicate the positions of the full - length ( uncleaved ) 22 -kDa Bid and the 15 - kDa form of Bid typical of the caspase - cleavage. Additional bands
representing partial degradation products are indicated by asterisks ( * ).
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and murine tissues by immunohistochemistry. The expres-
sion pattern was very similar in human and mouse tissues.
The Bid immunostaining was confined to the cytosol,
frequently revealing a coarse granular pattern. Representa-
tive examples of immunostaining results are provided in
Figure 2. It should be noted that because of the non-
quantitative nature of immunohistochemistry, these data
should be interpreted as only approximations of the relative
amounts of Bid in various types of cells in vivo.
Bid immunoreactivity was detected in neurons in the
peripheral and central nervous system. The peripheral
ganglia of the submucosal (Meissner’s) and myenteric
(Auerbach’s) plexus of the gastrointestinal tract, dorsal root
ganglia of spinal nerves, and axons of peripheral nerves
contained moderate levels of this protein. In the spinal cord,
motoneurons in the ventral horns, sensory neurons in the
dorsal horns, and intermediate neurons showed intense Bid
staining. In addition to neuronal cytosolic staining, Bid was
also present in dendrites (Figure 2D ). This proapoptotic
protein was also seen in glial cells. The most pronounced
expression was found in fibrillary astrocytes of the white
matter. The oligodendroglia contained lower levels of Bid and
microglial cells were negative.
The lymphoid system is another site of prominent Bid
expression. The highly apoptosis -prone germinal center B
cells (both small and large cells ) of secondary lymphoid
follicles in lymph nodes, tonsils, and spleen contained
moderate to strong Bid immunostaining, whereas the
surrounding long- lived mantle zone lymphocytes were either
only weakly positive or immunonegative (Figure 2B ). The
weak to moderate staining was present in some of the large
transformed lymphocytes but small resting lymphocytes in
this region were typically immunonegative for Bid. Thus,
expression of Bid in lymphocytes may be dynamically
regulated in vivo with changes in lymphocyte activation. In
the interfollicular region of lymph nodes, sinus histiocytes
and interdigitating dendritic cells contained high levels of Bid
protein (Figure 2C ). Macrophages in the splenic red pulp
showed very intense Bid immunoreactivity. In the white pulp,
lymphocytes constituting the marginal zone contained
moderate to high Bid staining (Figure 2A ). Strong staining
of macrophages was also found in other organs, such as
Figure 2. Immunohistochemical analysis of Bid expression in normal mouse and human tissues. (A ) In mouse spleen, Bid is expressed in themarginal zone where T
and B lymphocytes are loosely arranged encircling the parietal lymphatic sheath (original magnification, 100 ). (B, C ) Bid immunostaining is shown for a human
reactive lymph node. In (B ), Bid staining predominates in the large lymphocytes within the germinal center of a secondary follicle. In contrast to the germinal center,
lymphocytes in the mantle zone are mostly negative for Bid ( original magnification, 400 ). In (C ), interfollicular dendritic cells contain high levels of Bid (1000 ).
(D ) Mouse brain ( cortex ) is shown. The cell bodies and dendrites of cortical pyramidal neurons display intense staining for Bid (1000 ). (E, F ) Bid immunostaining
in stratified squamous epithelium of the epidermis and cervix are shown, respectively (1000 ). Note strong Bid immunoreactivity in cells of the upper layers of these
epithelia, and absence of Bid staining in undifferentiated cells along the basement membrane.
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lung (alveolar macrophages). In the thymus, the cortical
thymocytes were typically negative or weakly positive,
whereas roughly half of the medullary thymocytes contained
low to moderate levels of Bid. Thus, Bid expression may be
modulated during thymocyte differentiation.
Among the hematopoietic cells of the bone marrow, Bid-
positive monocytes and mature neutrophils dominated the
immunostaining results, followed by weakly positive mega-
karyocytes. The majority of myeloid precursors contained
only weak or no immunostaining. In the peripheral blood,
monocytes, granulocytes, and eosinophils showedmoderate
Bid immunoreactivity.
Bid was expressed at immunodetectable levels in several
epithelial tissues. The expression of this protein was
strongest in the upper layers of the epidermis and was only
weakly present in the basal cells lining the basement
membrane (Figure 2E ). Similar observations were made
for the stratified squamous epithelium of esophagus (not
shown) and cervix (Figure 2F ). The pseudostratified
tracheal and bronchial epithelium, and simple ductal epithelia
of the salivary glands, pancreas, liver, and endometrium in
uterus, as well as absorptive epithelium in the gastro-
intestinal tract also stained positive for Bid. The connec-
tive tissue fibroblasts contained weak to moderate Bid
immunoreactivity.
Hepatocytes and occasional Kupfer cells in the liver
demonstrated immunodetectable levels of Bid. In the kidney,
the epithelial cells in the thin loops of Henle, distal tubule, and
collecting ducts contained moderate levels of this protein.
In the testis, cells in various stages of spermato- and
spermiogenesis in the seminiferous tubules showed variable
Bid content, with the highest observed in spermatids. In the
prostate, the androgen-dependent secretory epithelial cells
lining the lumen contained low levels of this protein, whereas
the androgen- independent basal cells were immunonega-
tive. Bid expression in the ovary was found in the granulosa
cells of the growing and mature follicles, whereas germinal
epithelium, oocytes, and stromal cells were mostly immuno-
negative (not shown). In the breast, weak to moderate
immunoreactivity was detected in the cuboidal epithelium
lining the alveoli, and in the myoepithelial cells.
Cardiomyocytes and arterial smooth muscle contained
weak to moderate immunostaining, whereas resting endo-
thelial cells of established vessels expressed very low or no
Bid. Activated endothelial cells at sites of inflammation or
angiogenesis were not examined.
Bid Expression in Human Malignancies
The expression of Bid was examined in several types of
human cancers by immunohistochemical methods using
archival paraffin -embedded tumor specimens. Representa-
tive examples of immunostaining results are presented in
Figure 3.
We determined the immunohistochemical expression of
Bid in 59 gliomas, including 15 astrocytotic, 11 glioblasto-
mas, 20 oligodendroglial, and 13 ependymal tumors
obtained from surgical resection. The level of Bid expression
did not correlate with the grade of malignancy in astrocytic
tumors. In ependymomas, high levels of Bid were found in
anaplastic ependymomas (mean score=156), whereas
low-grade ependymal tumors expressed less protein (mean
score=96), although the results are not statistically signifi-
cant. Comparisons of the immunoscore data for oligoden-
drogliomas and astrocytomas revealed a statistically
significant higher expression of Bid in oligodendroglial
tumors ( t test P=0.04). No correlation was found between
progression of tumors (primary tumors versus recurrences)
and Bid immunoscore results when examining either all
tumors together or separately by histologic subtype.
The immunoreactivity of Bid was scored in 100 primary
colorectal adenocarcinomas, 60 of which contained residual
non-neoplastic epithelium for direct comparisons. Com-
pared to normal epithelium, Bid immunoscores were
elevated in 34 of 60 carcinomas (57%) (P=0.0002).
Patients were divided into three groups based on clinical
outcome: 1) those who survived without disease (n=59); 2)
survived with disease recurrence (n=10); and 3) those who
died from disease (n=31). Of the 34 cases with higher Bid
expression 17 (50%) died from disease, 1 (3%) survived
with disease recurrence, and 16 (47%) survived without
disease. Of the 26 cases with lower Bid expression, 4 (15%)
died from disease, 3 (12%) survived with disease recur-
rence, and 19 (73%) survived without disease. At6.5 years
of follow-up, half of the patients with high levels of Bid were
alive, whereas 70% of patients with low Bid levels remained
alive. However, these differences in survival for high and low
Bid expressors did not reach statistical significance. The
comparison of mean Bid scores among the three groups
revealed no significant differences.
Of the 95 ovarian cancers analyzed for Bid expression
(Figure 3A and B ), nearly all (94 of 95 cases) contained at
least 20% immunopositive cells. Examination of the immu-
noscoring data as a continuous variable failed to reveal a
significant correlation of Bid immunostaining with patient age
(60 vs. >60 years), clinical stage (FIGO I/ II vs. III / IV), or
response to chemotherapy (responder [CR, PR, NED]
versus nonresponder [PD, NC]). The follow-up time was
too short for this cohort of patients to assess correlations of
Bid with survival.
Tissue samples from 254 primary prostate cancers with
stage T1 to T3 disease were scored for Bid protein content
(Figure 3C ). Bid immunoscores were significantly higher in
Figure 3. Immunohistochemical analysis of Bid expression in tumors. Representative Bid immunostaining results are presented for microarrays of ovarian (A–B )
and prostate (C ) cancer specimens. Tissue microarray blocks were prepared using 1 -mm-diameter cylindrical punches of fixed tissue from 95 ovarian tumor
specimens or 0.4 -mm-diameter punches from 175 prostate cancers. (D ) Kaplan -Meier analysis is presented for prostate (T3 stage disease ) cancer patients,
showing the proportion of patients surviving alive without disease ( relapse - free survival [RFS ] ), for data dichotomized into high and low Bid immunoscore groups. In
(A–C), examples of Bid immunostaining are presented at original magnifications ranging from 2 to 200. In (A ), replicates of the ovarian cancer array were
stained using Bid peptide -preadsorbed antiserum ( left ), as a control, or with AR -54 anti –Bid antiserum ( right ).
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advanced prostate cancers, as defined by clinical stage (T1
vs. T3; P=0.0002). In the T1 and T2 groups, Bid immuno-
reactivity did not correlate with survival. However, higher Bid
immunoscores were associated with longer recurrence- free
survival (RFS) in the T3 group of prostate cancer patients
(P=0.04) (Figure 3D ). No significant correlation of Bid
immunostaining with patient age (70 vs. >70 years), or
Gleason grading was found.
The expression of Bid was explored in B-cell NHLs.
Patient specimens employed for these studies represented
archival paraffin blocks obtained from a variety of ECOG
trials (EST 6494). A total of 50 lymphoma specimens were
immunostained. Based on comparisons with non-neoplastic
nodes, the presence of 20% immunopositive malignant
lymphocytes was chosen as a cut-off for dichotomizing
immunostaining data into positive versus negative groups.
Using this method, 33 of 50 (66%) lymphomas were
determined to be Bid-positive. Larger proportions of
lymphomas with diffuse (22 of 29; 76%) versus nodular
( follicular ) (3 of 12; 25%) cytoarchitecture were Bid
immunopositive (P=0.002). Also, when immunoscore data
( intensitypercentage) were analyzed, diffuse lymphomas
were found to have an average of five- fold higher expression
of Bid compared to follicular lymphomas (scores 138±14.5
vs. 27±22.5) (P=0.0007). The expression of Bid in
lymphomas with mixed follicular and diffuse histology
(n=9; score 113) was similar to diffuse lymphomas (score
113±26.0 [n=9] vs. 138±14.5 [n=29]).
Immunoblot Analysis of Bid Protein in the NCI Panel of
Tumor Cell Lines
The relative levels of Bid protein in the NCI 60 tumor cell
line panel and in additional prostate and breast cancer cell
lines were characterized by immunoblot assay. ECL data on
X-ray films were quantified by scanning densitometry and
the relative amounts of Bid were estimated for each tumor
cell line, using recombinant GST-Bid protein to generate
standard curves for extrapolation, essentially as described
Figure 4. Immunoblot analysis of Bid protein in the NCI panel of tumor cell lines. The relative levels of Bid protein in the NCI 60 tumor cell line panel and in additional
prostate and breast cancer lines were characterized by immunoblot assay. ECL data on X- ray films were quantified by scanning densitometry and the relative
amounts of Bid were estimated for each tumor cell line, using recombinant GST -Bid protein to generate standard curves for extrapolation, essentially as described
[52 ]. (A ) summarizes the results, expressing the data as nanograms of Bid protein per milligram of total protein. (B ) provides examples of Bid immunoblot data for
11 tumor lines.
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[52]. Figure 4A summarizes the results, expressing the data
as nanograms of Bid protein per milligram of total protein.
Among the various tumor cell lines tested, leukemia and
lymphoma cell lines contained the highest amounts of Bid
(Figure 4A and B ). The promyelotic leukemia line HL60,
acute lymphoblastic leukemia line CCRF-CEM, and T-cell
acute lymphoblastic leukemia MOLT 4 expressed the
highest levels of this protein among all tumor lines
examined.
Bid protein was expressed at low to moderate levels in
most tumor cell lines, including breast, ovarian, colon,
prostate cancer, lung cancer, and CNS tumors. However,
some tumor cell lines lacked a detectable expression of Bid
protein, including 4 of 7 melanomas, 4 of 9 lung cancers, and
2 of 6 ovarian cancer cell lines (Figure 4A ).
Bid Expression Correlates with Cell Sensitivity to
Ribonucleotide Reductase Inhibitors
Bid protein levels were correlated with the chemo-
sensitivity data for compounds tested on the NCI 60 cell
line panel (Table 1). Bid expression positively correlated
with sensitivity to pyrimidine 5-glycodialdehyde and digly-
coaldehyde, two ribonucleotide reductase inhibitors, as well
as to pyrazine diazohydroxide (PZDH), an antitumor agent
that forms DNA adducts through the reactive pyrazine
diazonium ion.
To explore the role of Bid in cell death induction by
ribonuclease inhibitors, we tested whether Bid overexpres-
sion sensitized cells to pyrimidine 5-glycodialdehyde.
Prostate cancer PC-3 cell were transfected with pcDNA3
or with pcDNA3-Bid and treated with this compound. As
shown in Figure 5A D, neither the transfection with
pcDNA3-Bid alone (panel B) nor the incubation of pcDNA3
PC-3 cells with 10 nM pyrimidine 5-glycodialdehyde
(panel C) led to cell death. However, incubation of the
Bid- transfected cells with 10 nM pyrimidine 5-glycodialde-
hyde induced apoptosis (panel D), thus confirming a
potential role of the Bid protein in sensitizing tumors to
this agent.
Discussion
By generating specific anti -Bid sera, we have explored the in
vivo expression of this Bcl -2 family protein in normal tissues
and several types of cancer using an immunohistochemical
approach. As implied by previous Northern blotting experi-
ments [11], the expression of Bid is widespread, suggesting
a role for this protein in the regulation of cell life and death in
various types of cells. The survey of Bid expression in normal
tissues suggests a prominent role for this protein in the
nervous and lymphoid systems.
Interestingly, Bid appears to be present in cells that are
prone to apoptosis, such as the cells in upper layers of
stratified epithelia, enterocytes toward the apex of the
intestinal villi, terminally differentiated neurons, maturing
spermatids, and germinal center B cells. In spite of a
relatively ubiquitous presence of this proapoptotic protein in
normal tissues, mice deficient for Bid have no apparent
developmental abnormalities [56], thus illustrating the
redundancy of mechanisms regulating cell death. However,
it is possible that defects in apoptosis could occur in Bid-
deficient mice during times of stress. For example, when
Bid-deficient mice were challenged with anti -Fas antibody,
hepatocyte apoptosis was reduced compared to normal
animals [56]. Thus, although not required for developmental
cell death or for normal cell turnover in the adult, the Bid
protein may assume important roles in disease situations,
particularly where inflammatory stimuli invoke elaboration of
ligands of TNF family death receptors that are known to
activate Bid through caspase-8–mediated cleavage.
Immunohistochemical comparisons of Bid immunointen-
sity suggest that the expression of Bid may become elevated
in some tumors, such as gliomas, colon carcinomas, and
prostate cancers. Higher levels of Bid were also found in
more advanced (T3) prostate cancers compared to earlier
stage (T1, T2) tumors and in lymphomas with more
advanced histology (diffuse large cell versus follicular small
cell ). It is possible that elevated levels of this proapoptotic
protein are an indication of other compensatory defects in
apoptosis mechanisms that allow tumor cells to tolerate high
levels of Bid. For example, Bid cannot kill cells if either Bax or
Bak is not intact [57]. Also, phosphorylation of Bid by casein
kinases has recently been shown to render it resistant to
cleavage by caspase-8 [58]. Given that roughly half of
aggressive lymphomas are generally curable with combina-
tion chemotherapy, whereas low-grade lymphomas are not
Table 1. Bid Expression Correlates with Tumor Cell Line Sensitivity to
Ribonucleotide Reductase Inhibitors
Rank Name of drug Pearson P ( two tail )
1 Pyrimidine 5 -glycodialdehyde 0.5 0.00004
2 Diglycoaldehyde 0.49 0.00008
3 PZDH 0.47 0.00016
4 Fluorodopan 0.44 0.00037
5 Hydroxyurea 0.43 0.00062
6 Asaley 0.4 0.00173
7 Batracyclin 0.39 0.00211
8 Carmethizole 0.39 0.00221
9 Melphalan 0.38 0.00257
10 BCNU 0.38 0.00291
13 Chlorambucil 0.35 0.00632
27 Bryostatin 1 0.29 0.02534
34 Fludarabine -PO4 0.27 0.03943
73 VP-16 0.16 0.22201
92 Methotrexate 0.12 0.36811
109 Cisplatinum 0.09 0.45489
113 Flavopiridol 0.09 0.47077
120 Tamoxifen 0.09 0.50519
127 Vincristine sulfate 0.07 0.56246
150 Paclitaxel 0.03 0.81474
Bid protein levels were correlated with chemosensitivity data for compounds
tested on the NCI 60 cell line panel, and the results were analyzed using a
Bonferroni correction for multiple correlations and calculating P values from
two - tailed t distributions and Pearson correlation coefficients, essentially as
described [ 53 ]. Because of the large number of comparisons performed,
P0.0003 was considered statistically significant, as explained previously
[ 53 ]. Results were ranked according to Pearson coefficients.
Note that Bid expression positively correlated with the sensitivity to pyrimidine
5 - glycodialdehyde and diglycoaldehyde, two ribonucleotide reductase
inhibitors, as well as to PZDH, an antitumor agent that forms DNA adducts
through the reactive pyrazine diazonium ion.
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[59], it is interesting that Bid was higher in the lymphomas
with more advanced histology.
In the NCI panel of 60 human tumor cell lines, Bid
expression correlated positively with the sensitivity to
pyrimidine 5-glycodialdehyde and diglycoaldehyde, two
ribonucleotide reductase inhibitors, as well as to PZDH, an
antitumor agent that forms DNA adducts through the reactive
pyrazine diazonium ion. Statistical comparisons of Bid
expression versus the chemosensitivity to another ribonu-
cleotide reductase inhibitor, hydroxyurea, were of borderline
significance, but this agent also inhibits DNA polymerases
[60]. These findings are unlikely to be fortuitous, given that
such correlations were not seen for several other Bcl -2
family proteins, including BAD, Bcl -2, Bcl -XL, Bax, and Bak
[52] (and unpublished observations). Further evidence of a
role for Bid in dictating sensitivity of tumor cells to
ribonucleotide reductase inhibitors was obtained through
gene transfer experiments. Whereas control PC3 prostate
cancer cells were insensitive to cell death induction by 10 nM
pyrimidine 5-glycodialdehyde, incubation of the Bid- trans-
fected PC-3 cells with 10 nM pyrimidine 5-glycodialdehyde
induced apoptosis, thus confirming a role of this protein in
apoptosis mediated by ribonucleotide reductase inhibitors.
Upregulation of enzymes of nucleotide metabolism and
DNA biosynthesis, such as ribonucleotide reductase,
together with the concomitant down-modulation of the
purine and pyrimidine degradation enzymes, helps to
support the aberrant proliferation of transformed cells [61].
Ribonucleotide reductases, therefore, are considered excel-
lent targets for cancer chemotherapy. However, like all
anticancer drugs, clinical responses to these agents are
varied. It will therefore be interesting in future studies to
inquire whether differences in tumor levels of Bid represent
one of the determinants of variations in clinical responses to
ribonucleotide reductase inhibitors. Also of interest is the
mechanistic basis for why Bid correlates with sensitivity to
ribonucleotide reductase inhibitors and not other classes of
anticancer drugs. In this regard, it has been suggested that
some anticancer drugs in some types of tumors invoke a
pathway for apoptosis involving TNF family death receptors,
resulting in activation of caspase-8, and thus creating a
scenario where Bid might assume an important role
[41,62 –68]. Further studies are thus required to gain
greater insights into the biologic repercussions and the
clinical significance of the variability of Bid expression in
human neoplasms.
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